Your browser doesn't support javascript.
loading
Options for modulation of drug resistance in ovarian cancer.
Arts, H. J. G.; Van Der Zee, A. G. J.; De Jong, S.; De Vries, E. G. E..
Afiliación
  • Arts HJ; Departments of Gynaecological Oncology and Medical Oncology, University Hospital Groningen, The Netherlands.
Int J Gynecol Cancer ; 10(S1): 47-52, 2000 Jan.
Article en En | MEDLINE | ID: mdl-11240733
The objective of this paper is to present an update of mechanisms responsible for drug resistance in ovarian cancer and the possible therapeutic options to modulate this resistance using literature review with emphasis on data acquired in studies comprising ovarian tumor samples. The classic concepts on resistance in ovarian cancer, namely platinum and multidrug resistance, are briefly discussed, followed by a description of more recent insights concerning the role of apoptosis in the development of chemoresistance. A wide variety of mechanisms may be responsible for drug resistance in ovarian cancer. However, a growing body of evidence indicates that defects in the intra- and extracellular apoptotic pathways are an important cause of resistance to cytotoxic agents which opens several new treatment strategies.
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido